FINNENCE ▪ THE WIRE FILE
THE WIRE · № 60929
News■ Unclear/unknown
Quadria-backed Maxivision confidentially files for India IPO
KINDNews
DIRECTION■ Unclear/unknown
SOURCES1
ENTITIES2
STORY SIZESTANDALONE
FIRST SEEN2026-10-01 23:00 UTC
LAST UPDATE2026-10-01 23:00 UTC
STATEactive
01 THE MACHINE READ
WHY IT MATTERS.
A confidential India IPO filing signals continued primary-market activity but no listed impact yet.
Indian healthcare listing pipeline stays active
CATALYST TO WATCH
Public filing and price band reveal
MAIN RISK
Market conditions could delay the IPO
02 THE STORY SO FAR
THE RECORD, IN ORDER.
STANDALONE ITEM — NOT YET FOLDED INTO A DEVELOPING STORY.
03 WHO'S INVOLVED
ENTITIES ON FILE.
AFFECTEDHealthcare
CONTEXTIndia
04 RECEIPTS
THE SOURCE RECORD.
1 SOURCES CONFIRMED05 PROPAGATION
WHAT THIS TOUCHES.
→CORRELATIONshares Healthcare
Supreme Court denies Arizona’s bid to delay start of takeover of healthcare in state prisons2026-10-01 17:58 UTC
Supreme Court denies Arizona’s bid to delay start of takeover of healthcare in state prisons2026-10-01 17:58 UTC
←CORRELATIONshares India
India's factory growth climbs to 7-month high on surging demand, PMI shows2026-10-01 05:07 UTC
India's factory growth climbs to 7-month high on surging demand, PMI shows2026-10-01 05:07 UTC
←CORRELATIONshares Healthcare
New Phase 3 trial: A Phase 3 Study of Inebilizumab in Participants With Primary Membranous Nephropathy — Amgen2026-10-01 12:00 UTC
New Phase 3 trial: A Phase 3 Study of Inebilizumab in Participants With Primary Membranous Nephropathy — Amgen2026-10-01 12:00 UTC
←CORRELATIONshares Healthcare
New Phase 3 trial: Torvutatug Samrotecan Plus Bevacizumab as First-line Maintenance in Homologous Recombination Deficiency (HRD) Negative Advanced Epithelial Ovarian Cancer — AstraZeneca2026-10-01 12:00 UTC
New Phase 3 trial: Torvutatug Samrotecan Plus Bevacizumab as First-line Maintenance in Homologous Recombination Deficiency (HRD) Negative Advanced Epithelial Ovarian Cancer — AstraZeneca2026-10-01 12:00 UTC
←CORRELATIONshares Healthcare
New Phase 3 trial: A Phase 3 Study of [177Lu]Ludotadipep for Metastatic Castration-Resistant Prostate Cancer — FutureChem2026-10-01 12:00 UTC
New Phase 3 trial: A Phase 3 Study of [177Lu]Ludotadipep for Metastatic Castration-Resistant Prostate Cancer — FutureChem2026-10-01 12:00 UTC
←CORRELATIONshares Healthcare
New Phase 3 trial: A Study to Evaluate the Immune Response and Safety of a Vaccine Against Influenza in Adults 18-64 Years of Age — GlaxoSmithKline2026-10-01 12:00 UTC
New Phase 3 trial: A Study to Evaluate the Immune Response and Safety of a Vaccine Against Influenza in Adults 18-64 Years of Age — GlaxoSmithKline2026-10-01 12:00 UTC
KEEP READING THE MACHINE
Summaries are generated and may contain errors — every claim links its sources.